FDA Adverse Event Malfunction Summary report: N

VIGILA 1CR 65 CE

MDR report key: 5246168 · Received November 24, 2015

Report

Report Number
1028232-2015-04136
Event Type
Malfunction
Date Received
November 24, 2015
Date of Event
June 8, 2015
Report Date
November 9, 2015
Manufacturer
BIOTRONIK SE & CO. KG
Product Code
NVY
PMA / PMN Number
P980023
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

UPON RECEIPT, THE LEAD UNDER COMPLAINT WAS SUBJECTED TO AN EXTENSIVE ANALYSIS. THE PERFORMANCE OF THE LEAD WAS SCRUTINIZED, INCLUDING A VISUAL, MECHANICAL AND ELECTRICAL INSPECTION. THE ANALYSIS REVEALED SEVERE SIGNS OF WEAR BETWEEN 10 CM AND 15 CM PROXIMAL TO THE LEAD TIP. IN THIS AREA THE INSULATION WAS FOUND RUBBED THROUGH. THIS DAMAGE CAN BE CONSIDERED TO BE THE ROOT CAUSE FOR THE CLINICAL OBSERVATION OF NOISE. BASED ON THE CHARACTERISTICS AS WELL AS THE LOCATION OF THE DAMAGE, IT IS REASONABLE TO ASSUME THAT THE LEAD HAD BEEN SUBJECT TO SEVERE MECHANICAL STRESS IN THE IMPLANTED STATE. INTERACTION BETWEEN THE TRICUSPID VALVE AND THE LEAD SHOULD BE TAKEN INTO CONSIDERATION. DIAGNOSTIC IMAGES CLARIFYING THIS ASSUMPTION WERE NOT AVAILABLE. FURTHER ANALYSIS SHOWED SEVERAL CUTS IN THE LEAD BODY WHICH MOST LIKELY OCCURRED DUE TO MEANS OF MEDICAL INSTRUMENTS USED DURING THE EXPLANTATION PROCEDURE. THE ANALYSIS DID NOT REVEAL ANY SIGN OF A MATERIAL OR MANUFACTURING PROBLEM.

Description of Event or Problem · 1

OUS MDR - AFTER AN IMPLANTATION PERIOD OF ABOUT 20 MONTHS, OVERSENSING WAS OBSERVED DURING A FOLLOW UP ON (B)(6) 2015. ONE DAY LATER, OVERSENSING WAS AGAIN OBSERVED AND IN ADDITION, RV SENSING VALUES WERE REPORTED TO BE < 200 OHM. THE LEAD WAS REPLACE ON (B)(6) 2015 AND RETURNED TO BIOTRONIK FOR ANALYSIS. NO ADVERSE PATIENT SIDE EFFECTS HAVE BEEN REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
778660 VIGILA 1CR 65 CE ICD LEAD NVY BIOTRONIK SE & CO. KG 382901

Patients

Seq Age Sex Outcome Treatment
1 Hospitalization